Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
14.10
+0.03 (0.21%)
At close: May 19, 2025, 4:00 PM
14.07
-0.03 (-0.21%)
Pre-market: May 20, 2025, 8:08 AM EDT
Keros Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Keros Therapeutics stock ranges from a low of $15 to a high of $26. The average analyst price target of $21 forecasts a 48.94% increase in the stock price over the next year.
Price Target: $21.00 (+48.94%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Keros Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 3 | 3 | 3 | 3 | 3 |
| Hold | 4 | 6 | 6 | 6 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $41 → $26 | Buy | Maintains | $41 → $26 | +84.40% | May 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $25 | Strong Buy | Maintains | $40 → $25 | +77.30% | May 8, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $43 → $25 | Strong Buy | Maintains | $43 → $25 | +77.30% | Apr 9, 2025 |
| Wedbush | Wedbush | Hold Reiterates $15 | Hold | Reiterates | $15 | +6.38% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +183.69% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
28.64M
from 3.55M
Increased by 706.85%
Revenue Next Year
10.50M
from 28.64M
Decreased by -63.34%
EPS This Year
-2.41
from -5.00
EPS Next Year
-4.52
from -2.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 221.8M | 42.0M | 52.5M | ||
| Avg | 28.6M | 10.5M | 17.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6,148.2% | 46.6% | 400.0% | ||
| Avg | 706.8% | -63.3% | 64.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.99 | -3.05 | -3.05 | ||
| Avg | -2.41 | -4.52 | -4.52 | ||
| Low | -5.59 | -5.95 | -6.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.